American Origin Unverified This profile is unclaimed and has not been independently reviewed. Claim & get verified

Altimmune, Inc. (ALT)

$2.12 -2.30% NASDAQ: ALT · 15-min delayed

GAITHERSBURG, Maryland
Public · NASDAQ: ALT
57 employees
Founded 1997

Visit website Follow

$538.7MMarket cap

$41.0KRevenue · FY2025

-$88.1MNet income

57Employees

ALTNASDAQ

2005IPO

About Altimmune, Inc.

Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

This profile is unclaimed. An authorized representative can claim it free to control the page and activate the embeddable Verified badge.

Company facts

Founded: 1997
Type: Public · NASDAQ: ALT
Employees: 57
IPO date: Oct 6, 2005
Headquarters: 910 CLOPPER ROAD
GAITHERSBURG, Maryland 20878
Phone: (240) 654-1450
Industry: Pharmaceuticals
Website: Visit site

Incorporation record

Incorporated in: DE, United States
Registered office: Wilmington, US
Legal entity ID: 549300EOYCQ8SW3NVE64

Source: GLEIF, the global Legal Entity Identifier registry · checked Jul 26, 2026. A US headquarters does not always mean US incorporation.

Registry IDs

Ticker: ALT Nasdaq
SEC CIK: 1326190
LEI: 549300EOYCQ8SW3NVE64
EIN: 202726770
SIC: 2834 PHARMACEUTICAL PREPARATIONS

Explore our data studies: the biggest company in every US state · all rankings & reports.

Embed this company’s badge

Show Altimmune, Inc.’s American-company profile badge on a website — copy this HTML:

<a href="https://americancompanies.com/company/altimmune-inc/"><img src="https://americancompanies.com/badge/altimmune-inc.svg" alt="Altimmune, Inc. — American company profile on americancompanies.com" width="220"></a>

Is this your company?

This profile is unclaimed — any authorized owner can claim it free, control the page, and activate the embeddable Verified badge for their own website.

Claim this profile — free

Track American companies

Create a free account to follow Altimmune, Inc. and get an email when it moves sharply — real market data, 15-minute delayed.

Create free account

Reported figures

Financial summary

Revenue FY2025: $41.0K
Net income: -$88.1M
Total assets: $279.9M
Market cap: $538.7M

Source: SEC EDGAR · updated Jun 7, 2026

NASDAQ: ALT

$2.12 -2.30%

15-minute delayed · data by Polygon.io

Past year · hover for prices

$2.12 $6.18

52-week range

Market cap: $538.7M
Shares outstanding: 254.1M
Open: —
Day range: –
Prev close: —
Volume: —
IPO date: Oct 6, 2005

Altimmune, Inc. (ALT) Stock Price

Reported a net loss of $88.1M in FY2025.
Trading 66% below its 52-week high.

Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.

No reviews yet. Be the first to review Altimmune, Inc..

Write a review

Newsroom

News about Altimmune, Inc.

Metabolic Dysfunction-Associated Steatohepatitis Clinical Trial and Competitive Landscape Expands as 180+ Companies Target New Treatment Options | DelveInsight GlobeNewswire Inc. · 2026-10-21 · positive Can NVO's Semaglutide Push Create Growth Beyond Cardiometabolic Care? Zacks Investment Research · 2026-10-07 · neutral Why Is Altimmune (ALT) Up 14.2% Since Last Earnings Report? Zacks Investment Research · 2026-09-11 · positive Alcohol Use Disorder Market Set to Expand at a 12.1% CAGR During the Forecast Period (2026–2036), Owing to the Emergence of Novel Mechanisms Such as 5-HT3 Pathway, NOP Receptor, mGluR5 NAM, and Other | DelveInsight GlobeNewswire Inc. · 2026-06-08 · positive Pemvidutide Demonstrates Significant Metabolic Improvements in Patients with MASH in New 48‑Week IMPACT Phase 2b Data Presented at EASL 2026 GlobeNewswire Inc. · 2026-05-28 · positive Altimmune Announces Closing of $225 Million Oversubscribed Public Offering of Securities Benzinga · 2026-04-27 · positive

News & sentiment via Polygon.io

FAQ

Altimmune, Inc.: frequently asked questions

Is Altimmune, Inc. an American company?

Altimmune, Inc. is a US-based company headquartered in Gaithersburg, Maryland, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.

Where is Altimmune, Inc. headquartered?

Altimmune, Inc. is headquartered in Gaithersburg, Maryland, United States.

Is Altimmune, Inc. publicly traded?

Yes — Altimmune, Inc. is a publicly traded company. Its stock trades under the ticker symbol ALT on the NASDAQ.

What does Altimmune, Inc. do?

Altimmune, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.

When was Altimmune, Inc. founded?

Altimmune, Inc. was founded in 1997.

Explore